Selected Publications
Juluri R, Vuppalanchi R, Olson J, Unalp A, Van Natta ML, Cummings OW, Tonascia J, Chalasani N. Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol 2010 May 25. [Epub ahead of print]
Patton HM, Yates K, Ünalp-Arida A, Behling CA, Huang TT-K, Rosenthal P, Sanyal AJ, Schwimmer JB, and Lavine JE for the NASH CRN. Association between metabolic syndrome and liver histology among children with NAFLD. Am J Goastroenterol 2010 April 6 [Epub ahead of print].
Writing Committee member. Sanyal AJ, Chalasani NP, Kowdley KV, McCullough AJ, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Ünalp A, Van Natta ML, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis: PIVENS Trial Primary Results. N Engl J Med 362: 1675-1685, 2010.
Abdelmalek MF, Suzuki A, Guy G, Ünalp-Arida A, Colvin R, Johnson RJ, Diehl AM. Increased Fructose Consumption is Associated with Fibrosis Severity in Patients with NAFLD. Hepatology 51: 1961-1971, 2010.
Kistler KD, Molleston JP, Ünalp A, Abrams SH, Behling C, Schwimmer JB, and the NASH CRN Research Group. Symptoms and Quality of Life in Obese Children and Adolescents with Nonalcoholic Fatty Liver Disease. Aliment Pharmacol Ther 31: 396-406, 2010
Writing Committee member (Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Ünalp A, Tonascia J) for the NASH CRN. Treatment of non-alcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 31: 62-70, 2010.
Ünalp A, Ploth DW, Colvin R, Counts C, Shepp PH, Van Natta ML, Meinert CL. Does Poly-N-Acetyl Glucosamine Patch Use Reduce Arteriovenous Fistula and Graft Failure Rates in Hemodialysis Patients with End Stage Renal Disease? Am J Med Sci 338: 178-184, 2009
David K, Kowdley KV, Ünalp A, Kanwal F, Brunt EM, Schwimmer JB; NASH Clinical Research Network. Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 49: 1904-1912, 2009.
Vuppalanchi R, Ünalp A, Natta ML, Cummings OW, Sandrasegaran KE, Hameed T, Tonascia J, Chalasani N. Effects of Liver Biopsy Sample Length and Number of Readings on Histologic Yield for Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 7: 481-486, 2009.
Brunt EM, Kleiner DE, Wilson LA, Ünalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA; NASH Clinical Research Network. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD - clinicopathologic correlations from the Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology 49: 809-820, 2009.
Writing Committee member (Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Ünalp A, Tonascia J) for the NASH CRN. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 30: 88-96, 2009.
Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Ünalp A; for the NASH Clinical Research Network. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 48: 829-834, 2008.
Neuschwander-Tetri BA, Ünalp A, Creer MH; Nonalcoholic Steatohepatitis Clinical Research Network. Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels. Arch Intern Med 168: 663-666, 2008.
Ünalp A, Tonascia S, Meinert CL. Presentation in relation to publication of results from clinical trials. Contemp Clin Trials 28: 358-369, 2007.
Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, Unalp-Arida A, Vilela V, Yazici Y, Lockshin MD. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome. Arthritis Rheum 56: 2382-2391, 2007.
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ for the Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321, 2005
Heath EI, Canto MI, Wu TT, Piantadosi S, Hawk E, Ünalp A, Gordon G, Forastiere AA; CBET Research Group. Chemoprevention for Barrett's esophagus trial: Design and outcome measures. Dis Esophagus 16:177-186, 2003
Unalp A, Shafer C, Tonascia S, Meinert CL. FDA censoring of manufacturers' postmarketing commitments in HIV/AIDS drug approval letters. Am J Ther 7: 257-263, 2000
Meinert CL, Gilpin AK, Unalp A, Dawson C. Gender representation in trials. Control Clin Trials 21: 462-475, 2000
Gencbay M, Degertekin M, Ermeydan C, Unalp A, Turan F. Exercise electrocardiography test in patients with aortic stenosis. Differential features from that of coronary artery disease. Int J Cardiol 69: 281-287, 1999
Gencbay M, Turan F, Degertekin M, Eksi N, Mutlu B, Unalp A. High prevalence of hypercoagulable states in patients with recurrent thrombosis of mechanical heart valves. J Heart Valve Dis 7: 601-609, 1998
Unalp-Arida A. Time lag bias in publishing clinical trials [letter]. JAMA 279: 1952, 1998
Unalp A, Ruacan S, Firat D. Hospital-based cancer registry. Turk J Cancer 24: 127-137, 1994
